Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of l-asparaginase in human serum

Lanvers, Claudia; Pinheiro, João Paulo Vieira; Hempel, Georg; Wuerthwein, Gudrun; Boos, Joachim

doi:10.1016/s0003-2697(02)00232-4

Cited by 82 publications

(78 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, the assessment of asparaginase activity is often performed by the use of a reaction with indooxine. 17 In North America, an FDA-approved asparaginase activity assay is currently commercially available (AIBio Tech, Richmond, VA, USA. )…”

Section: What Should Be Measured?mentioning

confidence: 99%

Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation

et al. 2016

View full text Add to dashboard Cite

Section: What Should Be Measured?mentioning

confidence: 99%

Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation

et al. 2016

View full text Add to dashboard Cite

“…L-asparaginase activity was analyzed as described before. 26 After collection serum was isolated by centrifugation and stored immediately at À80 1C; serum levels of asparagine, aspartic acid, glutamine and glutamic acid were performed using high-performance liquid chromatography. 27 The lower limit of detection was 0.2 mM for all amino acids; glutamine levels higher than 250 mM were not further analyzed and reported as 4250 mM.…”

Section: Apoptotic Featuresmentioning

confidence: 99%

Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study

et al. 2008

View full text Add to dashboard Cite

L-asparaginase is an effective drug for treatment of children with acute lymphoblastic leukemia (ALL). The effectiveness is thought to result from depletion of asparagine in serum and cells. We investigated the clinical response in vivo of 1000 IU/m 2 pegylated (PEG)-asparaginase and its pharmacokinetic, pharmacodynamic and intracellular effects in children with newly diagnosed ALL before start of combination chemotherapy. The in vivo window response was significantly related to immunophenotype and genotype: 26/38 common/pre B-ALL cases, especially those with hyperdiploidy and TELAML1 rearrangement, demonstrated a good clinical response compared to 8/17 T-ALL (P ¼ 0.01) and BCRABL-positive ALL (P ¼ 0.04). A poor in vivo clinical window response was related to in vitro resistance to L-asparaginase (P ¼ 0.02) and both were prognostic factors for long-term event-free survival (hazard ratio 6.4, P ¼ 0.004; hazard ratio 3.7, P ¼ 0.01). After administration of one in vivo dose of PEG-asparaginase no changes in apoptotic parameters or in intracellular levels of twenty amino acids in leukemic cells could be measured, in contradiction to the changes found after in vitro exposure. This may be explained by the rapid removal of apoptotic cells from the circulation in vivo. One additional dose of PEG-asparaginase upfront ALL treatment did not lead to other severe toxicities.

show abstract

“…This method allowed the quantification of 2.5 IU/l ASP in human serum with coefficients of variation for intra-and interday variability of 1.98-8.77 and 1.73-11.0%, and an overall recovery of 10179.92%. 7 Asn levels in the plasma and CSF were measured using the RP-HPLC technique following precolumn derivation with o-phthaldialdehyde and fluorescence detection according to Lenda and Svenneby. 8 The lower limit of detection (LOD) was 0.2 mM.…”

Section: To the Editormentioning

confidence: 99%

Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL

et al. 2003

View full text Add to dashboard Cite

patients. 5 T cells with an enhanced expression of CD54 and a high IL-4 content were found in patients with asthma. 8 The biological significance and mechanism of upregulation of CD54 on T cells in B-CLL need, however, further clarification.This study showed that several critical activation/interaction molecules on T cells in B-CLL are abnormally expressed, and more pronounced by advanced stage. These defects may contribute to immune dysfunction responsible for immunological abnormalities and an impaired regulation of the leukemic clone. Therapeutic attempts might be instituted to restore T-cell functions, those interventions may be crucial when developing immunotherapeutic concepts, especially tumor vaccines.

show abstract

Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of l-asparaginase in human serum

Cited by 82 publications

References 27 publications

Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation

Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation

Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study

Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL

Contact Info

Product

Resources

About